Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Thursday, March 28, 2013
Wednesday, March 27, 2013
Stock Watch List for 03/27/2013, STSI, DNDN, UTSI, LIVE, get more picks
Rebound
plays:
DNDN
is near 52 week LOWS and ZIOP at all time LOWS!
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Tuesday, March 26, 2013
Stock watch list for 03/26/2013, DLGC, LEDS, OPXA, BVX, STEV, get more sign up today
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Monday, March 25, 2013
2 stocks to watch, 03/25/2013, STXS, StereoTaxis, PLUG, Plug Power, get more http://www.dailystockdeals.com/
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Sunday, March 24, 2013
GNIN, Green Innovations, Summary, Profile
GNIN,
Green Innovations, Summary, Profile
Green
Innovations Ltd is focused on filling a void in the eco-friendly,
biodegradable product array. As the world continues to trend away
from tree-based products in favor of products with smaller carbon
footprints, consumers are becoming more educated about the “green”
products that are available to them in the marketplace and are
consequently demanding higher standards for these products. In order
to help satisfy this demand, Green Innovations Ltd, through its
wholly-owned subsidiary Green Hygienics Inc., is the exclusive and
licensed North American distributor of American Hygienics Corporation
100% tree-free, bamboo-based product line, including personal care
and paper-based goods.
Our
products provide their end-users the opportunity to enjoy the quality
and performance delivered by a company that has been producing for
over a decade, the cost-benefit of a company that manufactures local
raw material, and the satisfaction of knowing that by using these
products they are doing their part to reduce their carbon footprint
and to continue the movement towards a more healthy and sustainable
planet.
Eco-Friendly Products
Bamboo products are far more earth-friendly than their conventional, paper-based alternatives. Bamboo can be grown and harvested in less than 5 years, during which time the bamboo will absorb more carbon dioxide and release more oxygen than a similarly-sized group of hardwood trees. Bamboo is a grass that does not require heavy chemical treatment to flourish, and unlike their hardwood counterparts, harvested bamboo fields maintain their root systems, which means less erosion and ultimately less chemical runoff.Finally, bamboo products such as diapers, wipes, and packaging that will potentially end up in landfills, will biodegrade at much faster rates than will petroleum-based diapers, cotton wipes, and foam packaging. Throughout the life cycle, the advantages of using bamboo are clear. We, at Green Innovations Ltd, are pleased to offer to you the many benefits of being greener by living tree free with an expanding line of bamboo-based products
Accreditations
FDA - Food and Drug Administration
The FDA is an executive department agency of the United States Department of Health and Human Services. The FDA is established to be responsible for protecting and promoting public health through regulation of consumer products. The FDA is one of the most recognized certifications in the world.
EPA - Environmental Protection Agency
An agency of the United States federal government which has been established for the purpose of protecting human health and the environment. The EPA's purpose is to protect consumers from significant risk from human health and the environment on which they live learn and work.
Nordic
Environmental Label The Nordic Ecolabel is a comprehensive evaluation through the lifecycle of the product. This means that, in developing criteria, we look at the whole life cycle of the product and all its related environmental issues. Climate considerations are thus a key element of the assessment. Some criteria contain requirements linked directly to the climate, such as those concerning use of fossil fuels or energy consumption during the manufacturing process. The more important we judge the climate issue to be for a particular product group, the stricter and more extensive the requirements become in that area.
BRC
– British Retail ConsortiumThe British Retail Consortium (BRC) is the lead trade association in the UK representing the whole range of retailers, from the large multiples and department stores through to independents, selling a wide selection of products through all levels of wholesale and retail. The BRC is a highly sought after certification in the UK as it is the authoritative voice of retail, recognized for its powerful campaigning and influence within government and as a provider of excellent retail information. The majority of UK, and many European and global retailers, and brand owners will only consider doing business with suppliers who have gained certification against the appropriate BRC Global Standard.
ISO
9001:2000 – International Organization for Standardization ISO International Standards ensure that products and services are safe, reliable and of good quality, they are strategic tools that reduce costs by minimizing waste and errors and increasing productivity. They help companies to access new markets, level the playing field for developing countries and facilitate free and fair global trade.
GMP
– Good Manufacturing PracticeGMP is a production and testing practice that maintains and ensures quality control of a manufactured goods. Many countries have created uniform GMP guidelines to correspond with their own legislation. These GMP guidelines safeguard the consumer and ensuring the goods produced are of the highest quality.
GMP is enforced in the United States by the Food and Drug Administration (FDA).
The World Health Organization (WHO) version of GMP is used by pharmaceutical regulators and the pharmaceutical industry in over one hundred countries worldwide, primarily in the developing world. The European Union's GMP (EU-GMP) enforces similar requirements to WHO GMP, as does the FDA 's version in the US. Similar GMPs are used in other countries, with Canada, Japan, Singapore, Philippines and others having highly developed/sophisticated GMP requirements.
Featured
Products
Toilet
Rolls of 100% bamboo pulp
- Cosmetic Wipes and Pads of 100% bamboo pulp
- Facial Tissue of 100% bamboo pulp
- Copy paper, notebooks and office papers of 100% bamboo pulp
- Meat platters (bamboo-styrofoam) for ground beef, steaks, etc.
- Cosmetic Wipes and Pads of 100% bamboo pulp
- Facial Tissue of 100% bamboo pulp
- Female Sanitary Pads
- Panty
Liners
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
we
received or expecting compensation from the featured company. Our
firm, principals and staff may own/buy/sell/trade stock/securities of
this company. Always Read the full Disclosure/Disclaimer. Thanks.
HALO, Halozyme, BAX, Baxter, announce positive results, 03/22/2013
HALO, Halozyme, BAX, Baxter, announce positive results, 03/22/2013
Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
"This recommendation supports our efforts to improve the overall quality of care for patients. This therapy, when approved by the European Commission, would offer patients the option to administer their therapy at home, in a single subcutaneous site every three to four weeks, resulting in potentially lower systemic adverse reactions compared to intravenous treatments," said Ludwig Hantson, Ph.D., president of Baxter's BioScience business. "We look forward to introducing HyQvia as a new patient-friendly therapeutic option for immunodeficient patients."
The application was based on results from a phase III, prospective, open-label, non-controlled design clinical trial, which evaluated the safety and effectiveness of HyQvia in the prevention of acute serious bacterial infections, and the pharmacokinetic parameters compared to immunoglobulin administered intravenously. The objective of the study was to infuse a 3-or 4-week dose of the therapy in a single subcutaneous site. The acute serious bacterial infection rate in the study was 0.025 per patient per year, which is below the required efficacy threshold of 1.0 (serious bacterial infections per patient per year). In the tolerability assessment of HyQvia, the most frequently reported adverse reactions were infusion site reactions (20% of infusions), headache (3% of infusions), fatigue (1% of infusions) and pyrexia (fever) (1% of infusions). Upon receiving marketing authorization from the European Commission, Baxter plans to launch HyQvia in selected countries in the European Union later this year.
"Recognizing that the path to approval for any biologic is a long journey, I would like to thank and congratulate the teams at Halozyme and Baxter who have worked tirelessly to advance this therapeutic option for patients," said Gregory I. Frost, Ph.D., president and chief executive officer, Halozyme Therapeutics.
Sources: Baxter, Halozyme, OxBridge Research, Daily Stock Deals
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
ANAC, Anacor Pharmaceuticals, announce positive results, 03/22/2013
ANAC,
Anacor Pharmaceuticals, announce positive results, 03/22/2013
Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic Dermatitis
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728. The study included 86 adolescents (ages 12 – 17) with mild-to-moderate atopic dermatitis, a chronic rash which predominantly affects children and is characterized by inflammation and itching. In this study, lesions treated with AN2728 ointment, 2.0% twice daily for 28 days achieved a 71% improvement from baseline in their Atopic Dermatitis Severity Index (ADSI) score, with 66% of lesions in this treatment group achieving total or partial clearance. AN2728 was generally safe and well-tolerated. Most adverse events were mild and largely unrelated to study drug.
“These results demonstrate a clear dose response across the four dosing regimens and identify the AN2728 ointment, 2.0% BID dosing regimen as optimal for a Phase 3 program, which we expect to initiate around the end of 2013,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “In all arms of the study, lesions treated with AN2728 ointment improved throughout the 28 day treatment period. The majority of the improvement occurred within the first week of treatment, which is important to both patients and physicians. AN2728 also continues to demonstrate an excellent safety profile - a key factor in treating this disease that primarily affects children.”
“There is a tremendous clinical need for safe and effective treatments for pediatric atopic dermatitis. It is very exciting to see these promising positive data for a novel molecule with excellent anti-inflammatory properties and that appears very safe to use,” said Lawrence F. Eichenfield, M.D., Chief of Pediatric and Adolescent Dermatology and Professor of Pediatrics and Medicine (Dermatology) at Rady Children's Hospital, University of California, San Diego. “AN2728 has the potential to be an outstanding addition to the treatment armamentarium for physicians and a great benefit to children with atopic dermatitis.”
Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic Dermatitis
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728. The study included 86 adolescents (ages 12 – 17) with mild-to-moderate atopic dermatitis, a chronic rash which predominantly affects children and is characterized by inflammation and itching. In this study, lesions treated with AN2728 ointment, 2.0% twice daily for 28 days achieved a 71% improvement from baseline in their Atopic Dermatitis Severity Index (ADSI) score, with 66% of lesions in this treatment group achieving total or partial clearance. AN2728 was generally safe and well-tolerated. Most adverse events were mild and largely unrelated to study drug.
“These results demonstrate a clear dose response across the four dosing regimens and identify the AN2728 ointment, 2.0% BID dosing regimen as optimal for a Phase 3 program, which we expect to initiate around the end of 2013,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “In all arms of the study, lesions treated with AN2728 ointment improved throughout the 28 day treatment period. The majority of the improvement occurred within the first week of treatment, which is important to both patients and physicians. AN2728 also continues to demonstrate an excellent safety profile - a key factor in treating this disease that primarily affects children.”
“There is a tremendous clinical need for safe and effective treatments for pediatric atopic dermatitis. It is very exciting to see these promising positive data for a novel molecule with excellent anti-inflammatory properties and that appears very safe to use,” said Lawrence F. Eichenfield, M.D., Chief of Pediatric and Adolescent Dermatology and Professor of Pediatrics and Medicine (Dermatology) at Rady Children's Hospital, University of California, San Diego. “AN2728 has the potential to be an outstanding addition to the treatment armamentarium for physicians and a great benefit to children with atopic dermatitis.”
Sources: Anacor Pharma, OxBridge
Research, Daily
Stock Deals
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Friday, March 22, 2013
Stock Watch list for 03/22/2013, ASTI, TXCC, CT, STP, HOKU, ETAK, for more daily deals visit DailyStockDeals.com
Thursday, March 21, 2013
3 Stocks to Watch 03/21/2013, PLUG, AFFY, DLIA more at http://www.dailystockdeals.com/
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Wednesday, March 20, 2013
2 Penny Stocks backed by the Federal Government, FNMA, FMCC, making tons of easy money!
See an Excellent Article here
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Tuesday, March 19, 2013
FMCC, FNMA, Freddie Mac, Fannie Mae, gain 60% in 2 days!
Penny Stocks backed by the Federal Government gain 60% in 2 days!
You could have made a whopping 60% gains on Penny Stocks backed by the Federal Government of the United States of America!
We Alerted Yesterday:
(see here) Daily Stock Deals @TOP10STOCKS18 Mar
Hot Stocks to Watch: $PULS $GALE $FMCC$FNMA http://www.dailystockdeals.com/topten/stocks-to-watch-03-18-2013-puls-gale-dcth-ffn-plug-stp-gigm-gold-is-back …
We detected unusual move yesterday, volume when through the roof, some 85 million shares traded and the stock gained a health 35% today.
Fannie Mae and Freddie Mac, the two government-seized mortgage financiers, appear increasingly likely to pay billions of dollars to the U.S. Treasury, focusing attention in Washington on what should replace them.
Edward J. DeMarco, the acting regulator of the two companies, appeared before the House Financial Services Committee today and urged lawmakers to reduce or eliminate the mortgage market’s reliance on taxpayers. At the same time, a Senate panel heard testimony from the authors of an alternate plan for housing-finance reform issued in February by an independent commission.
“I have been observing a developing ‘consensus’ among private-market participants that the conforming conventional mortgage market cannot operate without the American taxpayer providing the ultimate credit guarantee for most of the market,” DeMarco said in testimony at the House hearing. “That clearly is one outcome, but I do not believe it is the only outcome that can give our country a strong housing finance system. I believe that our country, and its financial system, are stronger than that.”
Washington-based Fannie Mae (FNMA) and McLean, Virginia-based Freddie Mac have been under U.S. conservatorship since 2008 and have drawn nearly $190 billion in taxpayer aid to stay afloat during that time. Lawmakers who don’t want the companies to return to their previous status as government-sponsored enterprises, or GSEs, are becoming concerned that political momentum for winding down and replacing them could erode as the housing market rebounds and profits soar.
Sources: Fannie Mae, Freddie Mac, OxBridge Research, Daily Stock Deals, Bloomberg
You could have made a whopping 60% gains on Penny Stocks backed by the Federal Government of the United States of America!
We Alerted Yesterday:
(see here) Daily Stock Deals @TOP10STOCKS18 Mar
Hot Stocks to Watch: $PULS $GALE $FMCC$FNMA http://www.dailystockdeals.com/topten/stocks-to-watch-03-18-2013-puls-gale-dcth-ffn-plug-stp-gigm-gold-is-back …
We detected unusual move yesterday, volume when through the roof, some 85 million shares traded and the stock gained a health 35% today.
Fannie Mae and Freddie Mac, the two government-seized mortgage financiers, appear increasingly likely to pay billions of dollars to the U.S. Treasury, focusing attention in Washington on what should replace them.
Edward J. DeMarco, the acting regulator of the two companies, appeared before the House Financial Services Committee today and urged lawmakers to reduce or eliminate the mortgage market’s reliance on taxpayers. At the same time, a Senate panel heard testimony from the authors of an alternate plan for housing-finance reform issued in February by an independent commission.
“I have been observing a developing ‘consensus’ among private-market participants that the conforming conventional mortgage market cannot operate without the American taxpayer providing the ultimate credit guarantee for most of the market,” DeMarco said in testimony at the House hearing. “That clearly is one outcome, but I do not believe it is the only outcome that can give our country a strong housing finance system. I believe that our country, and its financial system, are stronger than that.”
Washington-based Fannie Mae (FNMA) and McLean, Virginia-based Freddie Mac have been under U.S. conservatorship since 2008 and have drawn nearly $190 billion in taxpayer aid to stay afloat during that time. Lawmakers who don’t want the companies to return to their previous status as government-sponsored enterprises, or GSEs, are becoming concerned that political momentum for winding down and replacing them could erode as the housing market rebounds and profits soar.
Sources: Fannie Mae, Freddie Mac, OxBridge Research, Daily Stock Deals, Bloomberg
Monday, March 18, 2013
Got PULS? PLUG in for profit! PULS up 29%, PLUG up 21%, 03/18/2013 double digit winners
PULS SYN DCTH FFN STP GIGM BFLY GALE CSUN PLUG
29.17% 4.44% 3.10% 9.62% -8.41% 3.85% -1.18% 5.21% 4.75% 21.69%
29.17% 4.44% 3.10% 9.62% -8.41% 3.85% -1.18% 5.21% 4.75% 21.69%
GOFF jumps 110% on Golden Glory Resource deal, Goff Corp,03/18/2013
MEDELLIN,
Colombia, March 15, 2013 (GLOBE NEWSWIRE) -- via PRWEB -- Goff
Corporation ("Goff" or "the Company") (GOFF)
through its wholly owned subsidiary Golden Glory Resources S.A.
("Golden Glory"), has acquired 100% interest in mineral
leases in the Aguadas, Department of Caldas, Colombia area -- a
region well known for multiple gold discoveries within the past
several years as Colombia has opened its doors to global mining
interest.
The leases on LGC15011 or known the "La Frontera Prospect" are comprised of 1227 hectares of mineral leases in the Aguadas area, Department of Caldas, located about 60 kilometers south of Medellin in Colombia's northern region. The leases were acquired 100% from a Colombian mining company.
The Caldas Region is widely regarded in the mining investment community as one of Colombia's hottest gold exploration and production areas. In 2011 an estimated 55,908 kilograms of gold valued at over USD $2.8 billion were produced in that South American country (Source:USGS Yearbook 2011 Colombia). Approximately two-thirds of Colombian gold production has been from placer deposits in the Department of Antioquia, which is immediacy adjacent to and straddles about 30% of the leases where Golden Glory's La Frontera Project is located.
Exploration was carried out by previous leaseholders and several artisanal miners have produced gold from the La Frontera property. This data, combined with modern mining approaches and review led to the acquisition and new initiative being launched by Goff subsidiary Golden Glory Resources.
The leases on LGC15011 or known the "La Frontera Prospect" are comprised of 1227 hectares of mineral leases in the Aguadas area, Department of Caldas, located about 60 kilometers south of Medellin in Colombia's northern region. The leases were acquired 100% from a Colombian mining company.
The Caldas Region is widely regarded in the mining investment community as one of Colombia's hottest gold exploration and production areas. In 2011 an estimated 55,908 kilograms of gold valued at over USD $2.8 billion were produced in that South American country (Source:USGS Yearbook 2011 Colombia). Approximately two-thirds of Colombian gold production has been from placer deposits in the Department of Antioquia, which is immediacy adjacent to and straddles about 30% of the leases where Golden Glory's La Frontera Project is located.
Exploration was carried out by previous leaseholders and several artisanal miners have produced gold from the La Frontera property. This data, combined with modern mining approaches and review led to the acquisition and new initiative being launched by Goff subsidiary Golden Glory Resources.
Source:the company, OxBridge
Research
Hot Stocks to watch 03/18/2013, PULS, GALE, DCTH, FFN, PLUG, STP,FMCC,FNMA, GIGM,Gold is Back!
Today's
Top 10 Picks:-
PLUG,
SYN, DCTH, FFN, STP, GIGM, BFLY, GALE, CSUN, PULS
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Friday, March 15, 2013
how to make $275 million dollars? largest insider trading settlement SAC fined $600 million dollars
|
|
CR Intrinsic Agrees to Pay More than $600 Million in Largest-Ever Settlement for Insider Trading CaseInfographicFOR IMMEDIATE RELEASE2013-41
Washington,
D.C., March 15, 2013
— The Securities and Exchange Commission today announced that
Stamford, Conn.-based hedge fund advisory firm CR Intrinsic
Investors has agreed to pay more than $600 million to settle SEC
charges that it participated in an insider trading scheme
involving a clinical trial for an Alzheimer’s drug being jointly
developed by two pharmaceutical companies.
The
SEC
charged CR Intrinsic with insider trading
in November 2012, alleging that one of the firm’s portfolio
managers Mathew Martoma illegally obtained confidential details
about the clinical trial from Dr. Sidney Gilman, who was selected
by the pharmaceutical companies — Elan Corporation and Wyeth —
to present the final drug trial results to the public.
|
The
settlement filed today in federal court in Manhattan is the largest
ever in an insider trading case, requiring CR Intrinsic — an
affiliate of S.A.C. Capital Advisors — to pay $274,972,541 in
disgorgement, $51,802,381.22 in prejudgment interest, and a
$274,972,541 penalty.
IDRA, PGNX today's bio-pharma winners,03/15/2013
Progenics Pharmaceuticals, PGNX
Fourth quarter revenue totaled $8.9 million, up $6.7 million from the 2011 period, resulting primarily from the partnering transactions. For the full year, Progenics reported revenues of $14.0 million, compared to $84.8 million for 2011, a decrease primarily from 2011 recognition of the Salix collaboration.
Royalty income for the quarter was $0.8 million compared to $1.3 million in the fourth quarter of 2011, reflecting stocking activity in 2011. Royalty income for the year was $5.0 million compared to $3.0 million for 2011.
Net sales reported to Progenics by Salix (in millions):
|
|
Three
Months Ended
|
Year
Ended
|
|||
|
|
December
31,
|
September
30,
|
December
31,
|
||
|
|
2012
|
2011
|
2012
|
2012
|
2011
|
|
U.S.
|
$4.1 |
$8.0 |
$3.8 |
$29.2 |
$21.5 |
|
Ex-U.S.
|
1.1 |
0.8 |
1.1 |
4.0 |
5.5 |
|
Global
|
$5.2 |
$8.8 |
$4.9 |
$33.2 |
$27.0 |
- Completed underwritten public offering of 12,650,000 primary common shares resulting in $23.3 million net proceeds.
- Out-licensed C. difficile preclinical program for $5.0 million upfront payment (received in January) with potential future milestones and royalties.
- Fourth
quarter Relistor global net sales increased 8% from the third
quarter, but decreased 40% from the prior year period due to 2011
stocking activity. Annual Relistor global net sales increased 23%
over 2011.
- Acquired Molecular Insight Pharmaceuticals, expanding our oncology pipeline with diagnostic and small molecule therapeutic candidates targeting PSMA and prostate cancer.
- Reported
positive clinical data from a study of two novel radiolabeled small
molecule imaging agents -- 123I-MIP-1072 and
123I-MIP-1095 -- targeting PSMA.
Idera Pharmaceuticals (IDRA)
Financial Results
As of December 31, 2012, cash and cash equivalents totaled $10.1 million compared to $24.6 million at December 31, 2011.
Fourth Quarter Results
Net loss applicable to common stockholders for the three months ended December 31, 2012 was $6.5 million, or $0.24 per diluted share, compared to net loss applicable to common stockholders of $9.7 million, or $0.35 per diluted share, for the same period in 2011. There was no significant revenue recognized in the fourth quarter of 2012 or 2011. Research and development expenses for the three months ended December 31, 2012 totaled $3.1 million compared to $5.7 million for the same period in 2011. General and administrative expenses for the three months ended December 31, 2012, totaled $1.3 million compared to $1.5 million for the same period in 2011.
Full Year Results
Net loss applicable to common stockholders for the year ended December 31, 2012 was $22.5 million, or $0.81 per diluted share, compared to net loss applicable to common stockholders of $28.3 million, or $1.03 per diluted share, for 2011. Total revenues in each of the years ended December 31, 2012 and 2011 were $0.1 million. Research and development expenses for the year ended December 31, 2012 totaled $13.7 million compared to $18.0 million for 2011. General and administrative expenses for the year ended December 31, 2012 totaled $6.3 million compared to $7.9 million for 2011.
Source:
the company, OxBridge
Research Daily
Stock Deals
7 Top solar stock picks LDK, JASO, YGE, DSTI, TSL,STP, CSIQ, Stock picks for 03/15/2013
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Top 10 contrarian Stock Picks, ZGNX, KUTV, YOD, USU, IVAN, RNN, CNET, ECTE, DVOX, STRI,03/15/2013
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Thursday, March 14, 2013
Today's biggest winner, SVA, Sinovac,Stocks to watch 03/14/2013, PLUG,BLDP, WYY, OCLR
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Wednesday, March 13, 2013
Stock watch list for 03/13/13, DRL, SYNM, HEMP, IBIO, HEK, DVAX, trade with extreme caution, profit taking could drive the market down
We
think traders are getting a little nervous, a healthy pull back could
happen, so, be prepared to reverse your short term trading strategy.
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Our Best Picks from today, 03/12/2013,OCZ up 20% COOL up 24% WAVX up 13%. SSY skyrocketed 35% today.
Our
pick from 03/11/2013, SSY skyrocketed, up a whopping 35%
We
tweeted yesterday SSY had a double digit potential!
look
where it is today!
SunLink Health Systems Inc. (SSY)
0.81 0.21(35.00%) 4:00PM EDT|
Prev Close: |
0.60 |
|---|---|
|
Open: |
0.64 |
|
Bid: |
0.60
x 300 |
|
Ask: |
0.82
x 100 |
|
1y Target Est: |
2.35 |
|
Beta: |
1.84 |
|
Next Earnings Date: |
20-May-13 |
|
Day's Range: |
0.64
- 0.90 |
|---|---|
|
52wk Range: |
0.51 - 1.63 |
|
Volume: |
106,179 |
|
Avg Vol (3m): |
16,332 |
|
Market Cap: |
7.65M |
|
|
|
Tuesday, March 12, 2013
GLUU our pick from yesterday up 20% stocks to watch,OCZ, COOL, ZOOM, LVVV
Glu Mobile, Inc. (GLUU)
Nasdaq Real Time Price
Don’t
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!® Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Nasdaq Real Time Price
|
Prev Close: |
2.42 |
|---|---|
|
Open: |
2.93 |
|
Bid: |
2.76
x 2000 |
|
Ask: |
2.77
x 2200 |
|
1y Target Est: |
2.97 |
|
Beta: |
2.66 |
|
Next Earnings Date: |
1-May-13 |
|
Day’s Range: |
2.71
– 3.08 |
|---|---|
|
52wk Range: |
1.99 – 5.90 |
|
Volume: |
17,565,113 |
|
Avg Vol (3m): |
1,656,770 |
|
Market Cap: |
181.93M |
|
P/E (ttm): |
N/A |
|
EPS (ttm): |
-0.32 |
Monday, March 11, 2013
Potential double digit movers for 03/11/2013 GLCH, SKUL, VVTV, SSY,OXBT
These
stocks have high probability of potential breakout: SSY, GLCR, SKUL,
VVTV
Stock
watch List for 03/11/2013, BCCI, GETG, PIP, BRD, OXBT and more at
Daily Stock Deals.
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Thursday, March 7, 2013
Baristas,BCCI,BAPI, receives a new Symbol from NASDAQ Capital Markets
Baristas Receives NASDAQ Capital Market Symbol "BAPI"
SEATTLE, March 6, 2013 /PRNewswire/ -- Baristas Coffee Company, Inc. (BCCI), a fast growing U.S. based beverage and branded products company, has today announced that it has completed all requirements and that its application to receive a symbol to be traded on the NASDAQ Capital Market has been approved. The symbol issued to Baristas Coffee Company is (NASDAQ:BAPI).Baristas will continue to trade under the symbol OTCPK:BCCI throughout the application process and comment periods until such time as it completes its up listing and begins to trade on the NASDAQ Capital Markets at which time it will trade under the newly reserved symbol NASDAQ:BAPI.
The companies that are listed on NASDAQ Capital Market need to satisfy all the required qualifications for NASDAQ securities in Rule 4300. The companies also need to adhere to the corporate governance standards set by NASDAQ.
The NASDAQ Capital Market provides companies the required capital in order to grow their business. The NASDAQ Capital Market also provides a listing venue that promises to accommodate the different stages of corporate lives of the companies.
Barry Henthorn CEO commented; "This is an important step in the process of BCCI moving from the OTC to the NASDAQ Capital Market. We have worked diligently in conjunction with our advisors in order to be in a position to take this step and will continue to do so throughout the application, comments and approval process. We are committed to providing our investors transparency and oversight as we continue to develop and expand our business. We are confident that we will be able to meet all of the listing requirements to begin trading in a reasonable timeframe."
About Baristas Coffee Company (BCCI): Headquartered in the Seattle, Washington area, Baristas Coffee Company, Inc. was formed to create a national brand of drive-thru espresso stands. BCCI is accomplishing this by acquiring established businesses that fit its model, opening new locations, and by franchising. Baristas has separated itself from the competition with its "theme" of joining attractive female baristas in entertaining costumes preparing the finest beverages available on the market. Baristas can currently be found in six greater Seattle area locations as well as in Texas, Florida, Arizona, and Montana. Your state, Coming Soon!
For more information on this fascinating concept please visit us at www.baristas.tv
Source: the company, OxBridge
Research
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
we
received or expecting compensation from the featured company. Our
firm, principals and staff may own/buy/sell/trade stock/securities of
this company. Always Read the full Disclosure/Disclaimer. Thanks.
Baristas,BCCI,BAPI,bare
skin hot coffee,competing with starbucks,sbux,seatles best,green
mountain,gmcr
Stevia, STEV, pre-sold entire harvest, licensing revenues jump, earnings accelerate
Stevia Corp. Poised to Harvest First Crop in Vietnam
Current Harvest Pre-Sold as New Products Begin Sales Under License Contributing to Additional Earnings
INDIANAPOLIS, IN--(Marketwire - Mar 5, 2013) - Stevia Corp. ( OTCQB : STEV ) ("Stevia Corp" or the "Company"), a farm management company focused on the economic development of stevia, the fastest growing product in the alternative sweetener sector, is pleased to announce that the first major crop harvest in Vietnam is on track and on schedule.As previously announced, Stevia Corp anticipates its current crop harvest in Vietnam to generate in excess of USD$2 million in revenues from more than 1,000 tons of harvest. Current field reports indicate that the projected harvest expectations will easily be met.
George Blankenbaker, Stevia Corp President, comments, "Based on early test field results and current field crop conditions, we anticipate a strong harvest during March, April and May."
Expansion of the current model is planned in August and the Company intends to increase production by a factor of 5 times by next spring subject to adequate capital.
Mr. Blankenbaker adds, "We have already established the infrastructure to support our projected growth and we have farmers on a waiting list to participate in our program. Our major advantage is that proficient farmers are able to more than double their income by participating in our program. This creates a ripple effect of support and enthusiasm from all parties involved, making it much easier to manage high growth expansion."
Additional revenue is expected to be generated from the sale of the Company's proprietary products formulated with stevia extracts, probiotics and enzymes. More than 100 farm operators have tested the products with excellent results and the Company is now making the products commercially available for sale under license.
Mr. Blankenbaker concludes, "Our farm management model will generate the quickest path to profitability and near-term growth, but long-term there is significant opportunity to leverage our technology and increase revenue and margins and build brand value from our growing portfolio of proprietary products."
Further details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information visit: www.steviacorp.us.
About Stevia Corp. ( OTCQB : STEV )
Stevia Corp. is a farm management company focused on best practice agronomic competency in order to deliver high-value stevia through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. To date, the Company has acquired two grower supply contracts and three nursery fields in Vietnam. For more information visit: www.steviacorp.us.
About the Stevia Industry SectorWithin two years of the USA market opening, Nielsen-based retail consumption data indicated almost $1 billion of retail sales for the sector. In 2010, stevia products were launched across thirty-five countries and in 38 categories. Zenith International estimates worldwide sales of stevia extract reached 3,500 tons in 2010 with an overall market value of $285 million and forecasts the global market for stevia will reach 11,000 tons by 2014 requiring the tripling of stevia leaf production at the farm level to keep pace with consumer demand. For more information visit: www.steviacorp.us.
Source:
the company, OxBridge
Research
Wednesday, March 6, 2013
Power up your portfolio with solar stocks, top 8 solar stocks, YGE, JASO, TSL, HSOL, LDK, CSIQ, CSUN, SOL, small cap solar stock picks for 03/06/2013,Get Off the Grid
Solar
downstream is going mainstream as more residential and corporate
customers, specially in California and New Jersey, are re-powering
the Grid. Federal and State subsidies and the new marketing/financing
strategies are paying off.
Ironically
most solar customers, however, will stay on the old Grid. The total
installed base in the United States is still under 2%, so, the Solar
Power has a lot of room to grow, large companies like Solar City,
SCTY and Sun Power, SPWR are poised to benefit from the huge upsurge
in demand.
Our
Top 8 solar picks:-
YGE,
JASO, TSL, HSOL, LDK, CSIQ, CSUN, SOL
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
we
received or expecting compensation from the featured company. Our
firm, principals and staff may own/buy/sell/trade stock/securities of
this company. Always Read the full Disclosure/Disclaimer. Thanks.
Tuesday, March 5, 2013
HIMX up 18%, LEDS gained 22%, BLDP up 14%, DYAX rose 19%
| HIMX | OCLR | TSON | STSI | LEDS | BLDP | DYAX | PPHM | ANTH | GTAT |
|---|---|---|---|---|---|---|---|---|---|
| 18.02% | -2.50% | 2.27% | 7.61% | 22.00% | 14.38% | 19.57% | 3.97% | 8.58% | 2.64% |
 |
|
|
|
|
|
|
|
|
|
Small Cap Healthcare Stocks for 03/05/2013:ANTH, BLDP, HIMX, LEDS.
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
Get
the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up,
its FREE!
Subscribe to:
Posts (Atom)